drugset / Trial / NCT06525298
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Timeline
- Start
- 2024-09-09
- Primary completion
- 2027-09
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EIS-12656 | Unknown | — | Oral |
| Subject | Olaparib | Small molecule | — | — |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | — | — |